Disclosures. Triptans for Kids 5/16/13

Size: px
Start display at page:

Download "Disclosures. Triptans for Kids 5/16/13"

Transcription

1 5/16/13 Disclosures Triptans for Kids Amy A. Gelfand, MD Departments of Neurology and Pediatrics UCSF Child Neurology and Headache Center I receive grant funding from: NIH/NINDS UCSF CTSI And honoraria from Journal Watch Neurology Some off-label uses of medications will be discussed One-year period-prevalence for migraine by age and sex Victor et al, Cephalalgia,

2 5/16/13 PET activation in dorsolateral pons (locus ceruleus); contralateral to pain Akerman et al, Nature Reviews Neuroscience, 2011 Afridi et al Brain 2005 Migraine Diagnostic Criteria in Pediatrics A. At least 5 attacks B. Duration 1-72 hours C. At least two of: Pounding quality Moderate or severe intensity Unilateral or bilateral location Movement sensitivity D. At least one of: (can be inferred from behavior) Photophobia and phonophobia Nausea and/or vomiting E. Not attributable to another disorder Disability from Migraine Disability from headache can be measured using PedMIDAS Areas of disability: -Missed school 1 -Impaired performance in school 1 -Impaired ability to participate in sports and other extra-curricular activities Impact on Quality of Life Impact on other family members (parents, sibs) 1 Arruda, Neurology, 2012 ICHD-II, Cephalalgia,

3 5/16/13 Question #1 You re seeing a 15 year old girl who has migraine attacks twice a month. The pain during her attacks is severe and associated with photophobia and phonophobia, but not nausea or vomiting. Naproxen (Aleve) helps a bit but she is still not able to get out of bed during an attack. Would you: A) Refer her to Neurology for treatment recommendations B) Curbside Neurology regarding which triptan would be appropriate in her age group and what dose C) Prescribe a triptan yourself D) Prescribe another class of medication Expectations of efficacy for acute migraine agents No universally agreed upon primary end point for acute migraine trials Ideal: Pain-free within two hours every time you take it, with no recurrence over the next 24 hours, and no side effects. Practical: Pain-relief by two hours 50% of the time you take it, with usually no recurrence over the next 24 hours, and no intolerable side effects. Overview of Pediatric Acute Migraine Treatment Triptans Non-pharmacologic measures: Quiet, dark environment Encourage PO fluid intake Encourage sleep Positive Trial(s) in children and/or adolescents: 1) Sumatriptan (Imitrex) 2) Almotriptan (Axert)* 3) Rizatriptan (Maxalt)* 4) Zolmitriptan (Zomig) Pharmacologic measures: 1) Non-specific analgesics: Studied down to Age 4 Acetaminophen NSAIDs: Naproxen, Ibuprofen, Ketorolac 2) Dopamine receptor antagonists: e.g. prochlorperazine 3) Dihydroergotamine (DHE): IM, IV, NS 4) Opioids 5) Barbiturate containing compounds (i.e. Fioricet) 6) Triptans No positive trials (yet) in children or adolescents: 5) Naratriptan(Amerge): pharmacokinetics studied 6) Eletriptan (Relpax): one negative trial (placebo 57%) 7) Frovatriptan (Frova): not studied (except 15 yo in menstrual migraine) *FDA labeled for acute migraine in pediatric patients 3

4 5/16/13 Triptans: Mechanism of Action When to consider a triptan 5HT 1B/1D/1F agonists Child has moderate or severe pain with migraine attacks NSAIDs or acetaminophen inadequately treat the pain When not to consider a triptan History of stroke or myocardial infarction Uncontrolled hypertension Hemiplegic or basilar-type migraine Pregnancy (relative contra-indication) In someone with triptan overuse medication overuse headache; a risk when using triptans 10 triptan days/month for 3 months How should I counsel the patient to use a triptan? 1) Treat early, when pain is still mild Act when Mild 1 study: -Early/mild group: 53% 2-hr pain free rate vs 37.5% of mod/severe. -But still better late than never: placebo 17.5% 2) Just take one dose ignore the label 3) Limit use to 2 days per week (on average) to avoid medication overuse headache 1 Goadsby et al Cephalalgia

5 5/16/13 What medication interactions are there? 1) Avoid other 5HT 1B/1D agonists within the same 24 hour period: other triptans, dihydroergotamine (DHE) 2) Risk of serotonin syndrome from concurrent SSRI/ SNRI use is quite low, if any: Based upon their pharmacology, the involvement of triptans in contributing to a serotonin syndrome, either alone or in combination with other medications, seems Evans et al Headache 2008 implausible. What about side effects of triptans? Few Can have sensations of tightening in chest or throat CNS side effects (i.e. somnolence, asthenia) are more likely from unmasking of symptoms that are part of the attack that come after pain passes 1 If these effects were drug-effects, they should occur equally among those who respond and those who don t More common among triptan responders than nonresponders Equally likely among responders in placebo and triptan groups 1 Goadsby Cephalalgia 2007 Question #2 You would like to try a triptan to treat the 15 year old patient from Question #1. Which one would you choose? A) Sumatriptan PO B) Sumatriptan NS C) Frovatriptan PO D) Zolmitriptan NS E) Rizatriptan MLT Sumatriptan In clinical use in the U.S. since early 1990s OTC (sort of) in the UK since forms: Tablets Nasal spray (NS) Subcutaneous injection (SC) Rectal suppository (PR) Pediatric studies: PO: one negative trial, but SC: Open-label use suggests efficacy NS: 3 positive double-blind, placebo-controlled trials Labeled for use in year-olds in the UK, now generic so unlikely to ever get labeled in U.S. 5

6 5/16/13 Sumatriptan NS Ages studied Dose Used Pain Relief 6-9 years 1 20 mg 86% at 2 hours years mg 66% at 2 hours 8-17 years mg 64% at 2 hours 2004 Practice Parameter from American Academy of Neurology and Child Neurology Society: Sumatriptan nasal spray is effective and should be considered for the acute treatment of migraine in adolescents 4 1 Ueberall, Neurology, Winner, Pediatrics, Ahonen, Neurology, Lewis, Neurology, 2004 Almotriptan FDA-labeled for treatment of acute migraine in adolescents years old Available as a tablet: 6.25 mg and 12.5 mg Randomized, double-blind, placebo-controlled, parallel-group trial in year olds: 2h pain relief in 72-73% vs. 55%, p< Also an open-label adolescent study suggested benefit (pain relief 62% at 2 hrs) 2 1 Linder, Headache, Berenson, Headache, 2010 Rizatriptan Ages studied Rizatriptan studies Study design Treatment arms Primary endpoint FDA-labeled for treatment of acute migraine in ages 6-17 years Labeled dosing: <40 kg: 5 mg MLT 40 kg: 10 mg MLT Tic-tacs 6-17 yrs 1 Double-blind placebocontrolled crossover 6-17 yrs 2 RCT, parallelgroup yrs 3 Long-term open label use 5 or 10 mg MLT vs. placebo 5 or 10 mg MLT vs. placebo 5 or 10 mg MLT 2h pain relief: 74% vs. 36%, p< h pain free: 31% vs. 22%, OR 1.6(95% CI ), p=0.03 2h pain free attacks: 46% 2h pain relief attacks: 65% 1 Ahonen, Neurology, Ho, Cephalalgia, Hewitt, Headache,

7 5/16/13 Zolmitriptan Zolmitriptan Available as a tab, NS, or ZMT (orange melt) Nasal spray formulation: better absorption than sumatriptan NS, but only available in one (adult) dose so generally appropriate just for those > 40 kg. Positive trials: Ages studied Study Design 6-18 yrs 1 Double-blind placebocontrolled crossover Treatment arms 2.5 mg PO Zomig vs. placebo Endpoint 2h pain relief: 62% (64% in those <13) vs. 28%, p< yrs 2 Double-blind placebocontrolled crossover 5 mg NS vs. placebo 2h pain free: 39% vs 19%, p<0.01; Negative trial: A second oral trial was negative, placebo response rate very high (58%) 1 Evers, Neurology, Lewis, Pediatrics, 2007 Question #3 Your 15 year-old migraine patient responds within 2 hours to rizatriptan 10 mg MLT and has no side effects. However, about half the time the headache comes back the next morning. What do you tell her? A) There s no way to decrease the likelihood of recurrent headache B) Take a second dose of rizatriptan before bed C) Take naproxen with the rizatriptan Triptans combined with NSAIDS In adults, efficacy of 85 mg sumatriptan/500 mg naproxen (pain relief at 2 hours and sustained pain relief 2-24 hrs) is greater than that of either agent alone 1 Adolescents (n=622) treated over 12,000 attacks open-label without any serious adverse events, providing safety data for this combination in adolescents 2 Likely an NSAID/triptan class effect, so could substitute FDA-labeled triptans for the sumatriptan 1 Brandes, JAMA, McDonald, Headache,

8 5/16/13 Question #4 You re seeing a 7 year old whose migraine attacks are associated with significant nausea and vomiting. Prochlorperazine (Compazine) PR causes a dystonic reaction and does not relieve the headache. Which triptan might you consider for her? Summary Points Triptans have been studied in pediatric patients, and two are now FDA-labeled for use in pediatrics. For those who can tolerate oral medications during an attack: almotriptan (12-17) and rizatriptan (6-17) are both on label; sumatriptan is generic so generally covered. A) Sumatriptan PO B) Almotriptan PO C) Zolmitriptan NS D) Rizatriptan MLT For those who can t tolerate the oral route: sumatriptan NS is studied down to age 6, with zolmitriptan NS having better absorption so preferable for those >40 kg. Sumatriptan SC or PR also options. Whenever possible, combining the triptan with an NSAID is likely to be helpful. Helpful References Gelfand AA, Goadsby PJ, Treatment of Pediatric Migraine in the Emergency Room, Pediatric Neurology, 47 (2012) Need slides? GelfandA@neuropeds.ucsf.edu Ho TW et al, Efficacy and tolerability of rizatriptan in pediatric migraineurs: Results from a randomized, double-blind, placebo-controlled trial using a novel enrichment design. Cephalalgia 2012: 32: Ahonen K et al, A randomized trial of rizatriptan in migraine attacks in children, Neurology 2006; 67: Linder SL et al, Efficacy and tolerability of almotriptan in adolescents. A randomized, double-blind, placebocontrolled trial. Headache 2008; 48:

Adult & Pediatric Patients. Stanford Health Care, Division Pain Medicine

Adult & Pediatric Patients. Stanford Health Care, Division Pain Medicine Acute Treatment Strategies in Adult & Pediatric Patients Theresa Mallick Searle, MS, RN BC, ANP BC Disclosures Speakers Bureau: Allergan, Depomed Acute Treatment Strategies in Adult & Pediatric Patients

More information

Faculty Disclosures. Learning Objectives. Acute Treatment Strategies

Faculty Disclosures. Learning Objectives. Acute Treatment Strategies WWW.AMERICANHEADACHESOCIETY.ORG Acute Treatment Strategies Content developed by: Lawrence C. Newman, MD, FAHS Donna Gutterman, PharmD Faculty Disclosures LAWRENCE C. NEWMAN, MD, FAHS Dr. Newman has received

More information

ADVANCES IN MIGRAINE MANAGEMENT

ADVANCES IN MIGRAINE MANAGEMENT ADVANCES IN MIGRAINE MANAGEMENT Joanna Girard Katzman, M.D.MSPH Assistant Professor, Dept. of Neurology Project ECHO, Chronic Pain Program University of New Mexico Outline Migraine throughout the decades

More information

Page: 1 of 5. Sumatriptan Tablets and Nasal Spray (Imitrex) / sumatriptan and naproxen sodium (Treximet tablets)

Page: 1 of 5. Sumatriptan Tablets and Nasal Spray (Imitrex) / sumatriptan and naproxen sodium (Treximet tablets) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 0 Subject: Sumatriptan (Imitrex / Treximet) Page: 1 of 5 Last Review Date: September 12, 2014 Sumatriptan

More information

Maxalt. Maxalt / Maxalt-MLT (rizatriptan) Description. Section: Prescription Drugs Effective Date: April 1, 2016

Maxalt. Maxalt / Maxalt-MLT (rizatriptan) Description. Section: Prescription Drugs Effective Date: April 1, 2016 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Maxalt Page: 1 of 5 Last Review Date: March 18, 2016 Maxalt Description Maxalt / Maxalt-MLT (rizatriptan)

More information

MEASURE #1: MEDICATION PRESCRIBED FOR ACUTE MIGRAINE ATTACK Headache

MEASURE #1: MEDICATION PRESCRIBED FOR ACUTE MIGRAINE ATTACK Headache MEASURE #1: MEDICATION PRESCRIBED FOR ACUTE MIGRAINE ATTACK Headache Measure Description Percentage of patients age 12 years and older with a diagnosis of migraine who were prescribed a guideline recommended

More information

A case of a patient with chronic headache. Focus on Migraine. None related to the presentation Grants to conduct clinical trials from: Speaker bureau:

A case of a patient with chronic headache. Focus on Migraine. None related to the presentation Grants to conduct clinical trials from: Speaker bureau: Chronic Daily Headache Bassel F. Shneker, MD, MBA Associate Professor Vice Chair, OSU Neurology The Ohio State University Wexner Medical Center Financial Disclosures None related to the presentation Grants

More information

HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in

HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in Anesthesia and Neurology Harvard Medical School Limited time

More information

Zomig. Zomig / Zomig-ZMT (zolmitriptan) Description

Zomig. Zomig / Zomig-ZMT (zolmitriptan) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.22 Subject: Zomig Page: 1 of 5 Last Review Date: March 16, 2018 Zomig Description Zomig / Zomig-ZMT

More information

Zomig. Zomig / Zomig-ZMT (zolmitriptan) Description

Zomig. Zomig / Zomig-ZMT (zolmitriptan) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.22 Subject: Zomig Page: 1 of 5 Last Review Date: November 30, 2018 Zomig Description Zomig / Zomig-ZMT

More information

MIGRAINE UPDATE. Objectives & Disclosures. Learn techniques used to diagnose headaches. Become familiar with medications used for headache treatment.

MIGRAINE UPDATE. Objectives & Disclosures. Learn techniques used to diagnose headaches. Become familiar with medications used for headache treatment. MIGRAINE UPDATE Karen L. Bremer, MD November 16, 2018 Objectives & Disclosures Learn techniques used to diagnose headaches. Become familiar with medications used for headache treatment. Disclosure: I am

More information

ISSN doi: /head VC 2015 American Headache Society Published by Wiley Periodicals, Inc.

ISSN doi: /head VC 2015 American Headache Society Published by Wiley Periodicals, Inc. ISSN 0017-8748 Headache doi: 10.1111/head.12746 VC 2015 American Headache Society Published by Wiley Periodicals, Inc. Review Article Acute Treatment Therapies for Pediatric Migraine: A Qualitative Systematic

More information

Pharmacy Medical Necessity Guidelines: Migraine Medications

Pharmacy Medical Necessity Guidelines: Migraine Medications Pharmacy Medical Necessity Guidelines: Effective: September 18, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED)

More information

How do we treat migraine? New SIGN Guidelines

How do we treat migraine? New SIGN Guidelines How do we treat migraine? New SIGN Guidelines Managing your migraine Migraine Trust, Edinburgh 2018 Callum Duncan Consultant Neurologist Aberdeen Royal Infirmary Chair SIGN Guideline 155 Premonitory Mood

More information

Regulatory Status FDA approved indication: Migranal Nasal Spray is indicated for the acute treatment of migraine headaches with or without aura (1).

Regulatory Status FDA approved indication: Migranal Nasal Spray is indicated for the acute treatment of migraine headaches with or without aura (1). Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.60 Subject: Migranal Nasal Spray Page: 1 of 5 Last Review Date: November 30, 2018 Migranal Nasal Spray

More information

Literature Scan: Triptans

Literature Scan: Triptans Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Migranal Nasal Spray. Migranal Nasal Spray (dihydroergotamine) Description

Migranal Nasal Spray. Migranal Nasal Spray (dihydroergotamine) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.60 Subject: Migranal Nasal Spray Page: 1 of 5 Last Review Date: June 22, 2017 Migranal Nasal Spray

More information

Abortive Agents. Available Strengths. Formulary Limits. Tablet: 5mg, 10mg ODT: 5mg, 10 mg 25mg, 50mg, 100mg. 5mg/act, 20mg/act

Abortive Agents. Available Strengths. Formulary Limits. Tablet: 5mg, 10mg ODT: 5mg, 10 mg 25mg, 50mg, 100mg. 5mg/act, 20mg/act MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Migraine Therapy P&T DATE: 9/12/2017 CLASS: Neurological Disorders REVIEW HISTORY 12/16, 9/15, 2/15, 2/10, 5/07 LOB: MCL

More information

I have no financial relationships to disclose. I will not discuss investigational use of medication in my presentation.

I have no financial relationships to disclose. I will not discuss investigational use of medication in my presentation. I have no financial relationships to disclose. I will not discuss investigational use of medication in my presentation. In 1962, Bille published landmark epidemiologic survey of headache among 9,000 school

More information

The best defense is a good offense. Optimizing the Acute Treatment of Migraine. Disclosures 11/10/2017

The best defense is a good offense. Optimizing the Acute Treatment of Migraine. Disclosures 11/10/2017 Optimizing the Acute Treatment of Migraine Brian M. Plato, DO, FAHS Norton Neuroscience Institute Louisville, KY Disclosures Speakers Bureau (personal): Allergan, Depomed, Avanir Research Funding (paid

More information

Anti-Migraine Agents

Anti-Migraine Agents DRUG POLICY BENEFIT APPLICATION Anti-Migraine Agents Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions

More information

Sumatriptan Tablets, Nasal Spray (Imitrex), Nasal Powder (Onzetra Xsail), sumatriptan and naproxen sodium (Treximet tablets)

Sumatriptan Tablets, Nasal Spray (Imitrex), Nasal Powder (Onzetra Xsail), sumatriptan and naproxen sodium (Treximet tablets) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 05.70.10 Subject: Sumatriptan Page: 1 of 5 Last Review Date: December 2, 2016 Sumatriptan Description Sumatriptan

More information

Headache Questionnaire

Headache Questionnaire Date: All Headache Patients We would appreciate your cooperation in filling out this form. In our evaluation of headache, your history is typically our most valuable tool for diagnosis and subsequent treatment.

More information

ONZETRA XSAIL (sumatriptan) nasal powder

ONZETRA XSAIL (sumatriptan) nasal powder ONZETRA XSAIL (sumatriptan) nasal powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy

More information

Acute Migraine Treatment in Adults

Acute Migraine Treatment in Adults PL Detail-Document #301104 This PL Detail-Document gives subscribers additional insight related the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER November 2014 Acute Migraine Treatment

More information

Headache A Practical Approach

Headache A Practical Approach Headache A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD Neurosciences Institute/Neurosciences Clinical Program Medical Director Headache and Pain Development Teams Disclosures:

More information

Triptans Quantity Limit Program Summary

Triptans Quantity Limit Program Summary Triptans Quantity Limit Program Summary FDA APPROVED INDICATIONS AND DOSAGE 1-13,14,23,24 Agents Amerge (naratriptan) 1, 2.5 tablets Axert (almotriptan) 6.25, 12.5 tablets migraine attacks with/without

More information

Management of headache

Management of headache Management of headache TJ Steiner Imperial College London Based on European principles of management of common headache disorders TJ Steiner, K Paemeleire, R Jensen, D Valade, L Savi, MJA Lainez, H-C Diener,

More information

Faculty Disclosure. Karen L. Bremer, MD. Dr. Bremer has listed no financial interest/arrangement that would be considered a conflict of interest.

Faculty Disclosure. Karen L. Bremer, MD. Dr. Bremer has listed no financial interest/arrangement that would be considered a conflict of interest. Faculty Disclosure Karen L. Bremer, MD Dr. Bremer has listed no financial interest/arrangement that would be considered a conflict of interest. HEADACHE UPDATE Karen L. Bremer, MD November 10, 2017 karen.bremer@creighton.edu

More information

Case Presentation. Case Presentation. Case Presentation. Truths about Headaches (2017) Most headaches were muscle-tension headaches

Case Presentation. Case Presentation. Case Presentation. Truths about Headaches (2017) Most headaches were muscle-tension headaches Agenda Case presentation Migraine Morphology Primary and Premonitory Phase Secondary Headache Aura Headache Primer on Pain Medication Overuse Headache Case Presentation RT is a 25 year old woman with daily

More information

Clinical Learning Days November 10, 2017

Clinical Learning Days November 10, 2017 Migraine Clinical Learning Days November 10, 2017 Alyssa Lettich. MD Neurosciences Institute/Neurosciences Clinical Program Medical Director Headache Disclosures: none Learning Objectives: At the conclusion

More information

Short Clinical Guidelines: Headache, Key Points for Diagnosis and Treatment

Short Clinical Guidelines: Headache, Key Points for Diagnosis and Treatment Clinical Highlights 1. Headache is diagnosed by history and physical examination with limited need for imaging or laboratory tests. 2. Warning signs of possible disorder other than primary headache are:

More information

Paediatric headaches. Dr Jaycen Cruickshank Director of Clinical Training Ballarat Health Services. Brevity, levity, repetition

Paediatric headaches. Dr Jaycen Cruickshank Director of Clinical Training Ballarat Health Services. Brevity, levity, repetition Paediatric headaches Dr Jaycen Cruickshank Director of Clinical Training Ballarat Health Services Brevity, levity, repetition Paediatric)headache?)! Headache!in!children!is!not!that!common.!The!question!is!which!headaches!do!I!

More information

Drug Class Review Triptans

Drug Class Review Triptans Drug Class Review Triptans April 2013 Last Report: Update #4 (June 2009) The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different

More information

Clinical Policy: Triptans Reference Number: CP.CPA.217 Effective Date: Last Review Date: Line of Business: Commercial

Clinical Policy: Triptans Reference Number: CP.CPA.217 Effective Date: Last Review Date: Line of Business: Commercial Clinical Policy: Reference Number: CP.CPA.217 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Sumatriptan Tablets, Nasal Spray (Imitrex), Nasal Powder (Onzetra Xsail), sumatriptan and naproxen sodium (Treximet tablets)

Sumatriptan Tablets, Nasal Spray (Imitrex), Nasal Powder (Onzetra Xsail), sumatriptan and naproxen sodium (Treximet tablets) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 0 Subject: Sumatriptan Page: 1 of 6 Last Review Date: November 30, 2018 Sumatriptan Description Sumatriptan

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Sumatriptan Tablets, Nasal Spray (Imitrex), Nasal Powder (Onzetra Xsail), sumatriptan and naproxen sodium (Treximet tablets)

Sumatriptan Tablets, Nasal Spray (Imitrex), Nasal Powder (Onzetra Xsail), sumatriptan and naproxen sodium (Treximet tablets) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 05.70.10 Subject: Sumatriptan Page: 1 of 6 Last Review Date: March 16, 2018 Sumatriptan Description Sumatriptan

More information

Drug Therapy Guidelines

Drug Therapy Guidelines Drug Therapy Guidelines Applicable Medical Benefit Effective: 5/1/18 Pharmacy- Formulary 1 x Next Review: 3/19 Pharmacy- Formulary 2 x Date of Origin: 8/29/06 Triptans: almotriptan, Amerge, Axert, Frova,

More information

Clinical Policy: Triptans Reference Number: CP.HNMC.217 Effective Date: Last Review Date: Line of Business: Medicaid Medi-Cal

Clinical Policy: Triptans Reference Number: CP.HNMC.217 Effective Date: Last Review Date: Line of Business: Medicaid Medi-Cal Clinical Policy: Reference Number: CP.HNMC.217 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important

More information

Outpatient Headache Care Guideline

Outpatient Headache Care Guideline 1 Outpatient Care Guideline Inclusion criteria: children > 3 yrs with headaches Is urgent emergency department, neuroimaging, or Neurology consultation indicated? Referral to ED if: New severe headache

More information

SUMAVEL DOSEPRO (sumatriptan succinate) solution for injection

SUMAVEL DOSEPRO (sumatriptan succinate) solution for injection SUMAVEL DOSEPRO (sumatriptan succinate) solution for injection Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit

More information

Drug Class Review Triptans

Drug Class Review Triptans Drug Class Review Triptans Preliminary Update Scan #3 February 2014 Last Report: Update #4 (June 2009) The purpose of reports is to make available information regarding the comparative clinical effectiveness

More information

Migraine Migraine Age Specific Prevalence in the United States. Headache International Headache Society Classification

Migraine Migraine Age Specific Prevalence in the United States. Headache International Headache Society Classification 28 Primary Care Medicine Principles and Practice 29 October 28 Professor Peter J. Goadsby Peter.Goadsby@headache.ucsf.edu Department of Neurology Headache International Headache Society Classification

More information

MIGRAINE A MYSTERY HEADACHE

MIGRAINE A MYSTERY HEADACHE MIGRAINE A MYSTERY HEADACHE The migraine is a chronic neurological disease that is characterized by moderate to severe episodes of headache that is mostly associated with other central nervous system (CNS)

More information

Çiçek Wöber-Bingöl HEADACHE UNIT FOR CHILDREN AND ADOLESCENCE

Çiçek Wöber-Bingöl HEADACHE UNIT FOR CHILDREN AND ADOLESCENCE Headache in children and adolescents Çiçek Wöber-Bingöl HEADACHE UNIT FOR CHILDREN AND ADOLESCENCE Dept. of Psychiatry of Childhood and Adolescence Medical University of Vienna, Vienna, Austria Impact

More information

UTILIZATION MANAGEMENT CRITERIA

UTILIZATION MANAGEMENT CRITERIA SUMATRIPTAN (ALSUMA, IMITREX, SUMAVEL DOSEPRO, ZECUITY ) UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: BRAND (generic) NAME: Serotonin 5-HT1 receptor agonists Imitrex (sumatriptan), Alsuma (sumatriptan),

More information

Clinical Policy: Triptans Reference Number: CP.CPA.217 Effective Date: Last Review Date: Line of Business: Commercial

Clinical Policy: Triptans Reference Number: CP.CPA.217 Effective Date: Last Review Date: Line of Business: Commercial Clinical Policy: Reference Number: CP.CPA.217 Effective Date: 11.16.16 Last Review Date: 11.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Page: 1 of 6. Aimovig (erenumab-aooe) injection, Ajovy (fremanezumab-vfrm) injection, Emgality (galcanezumab-gnim)

Page: 1 of 6. Aimovig (erenumab-aooe) injection, Ajovy (fremanezumab-vfrm) injection, Emgality (galcanezumab-gnim) Page: 1 of 6 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Last Review Date: November 30, 2018 Description Aimovig (erenumab-aooe) injection, Ajovy (fremanezumab-vfrm)

More information

5 HT receptor agonists (triptans) and Pediatric Migraine Critically Appraised Topic (CAT)

5 HT receptor agonists (triptans) and Pediatric Migraine Critically Appraised Topic (CAT) 5 HT receptor agonists (triptans) and Pediatric Migraine Critically Appraised Topic (CAT) PICOT Question: In children and adolescents does use of 5 HT receptor agonists (triptans) versus no treatment treat

More information

Migraine Acute treatment

Migraine Acute treatment Migraine Acute treatment Elizabeth Loder, MD, MPH Professor of Neurology, Harvard Medical School Chief, Division of Headache, Department of Neurology, Brigham and Women s Hospital, Boston, MA Disclosures

More information

ABORTIVE AGENTS. Average cost per 30 days. Form Limits SEROTONIN AGONISTS $ $ Reserved for treatment failure to either Sumatriptan PA; QL

ABORTIVE AGENTS. Average cost per 30 days. Form Limits SEROTONIN AGONISTS $ $ Reserved for treatment failure to either Sumatriptan PA; QL MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Migraine Therapy P&T DATE: 12/11/2018 CLASS: Neurological Disorders REVIEW HISTORY 9/17, 12/16, 9/15, 2/15, 2/10, LOB: MCL

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

...SELECTED ABSTRACTS...

...SELECTED ABSTRACTS... The following abstracts, from medical journals containing literature on migraine management, were selected for their relevance to this Special Report supplement. Two Sumatriptan Studies Two double-blind

More information

Imitrex for ocular migraines

Imitrex for ocular migraines Imitrex for ocular migraines Information about ocular, optical, and ophthalmic Migraine, accurate diagnoses, and the importance of correct diagnostic and classification terminology. 14-10-2015 1 Answer

More information

Sumatriptan Injection (Imitrex / Alsuma / Sumavel / Zembrace)

Sumatriptan Injection (Imitrex / Alsuma / Sumavel / Zembrace) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.11 Subject: Sumatriptan Injection Page: 1 of 6 Last Review Date: March 16, 2018 Sumatriptan Injection

More information

Update on Diagnosis and Management of Migraines

Update on Diagnosis and Management of Migraines Update on Diagnosis and Management of Migraines Joel J. Heidelbaugh, MD, FAAFP, FACG Clinical Professor Departments of Family Medicine and Urology University of Michigan Learning Objectives To distinguish

More information

Migraineurs have specific preferences with regard to migraine therapy. In surveys,

Migraineurs have specific preferences with regard to migraine therapy. In surveys, Patient Treatment Preferences and the 5-HT 1B/1D Agonists Robert E. Ryan, Jr, MD REVIEW ARTICLE Migraineurs have specific preferences with regard to migraine therapy. In surveys, they consistently cite

More information

Pharmacy Updates Summary

Pharmacy Updates Summary All of the following changes were reviewed and approved by the SFHP Pharmacy & Therapeutics (P&T) Committee on 4/16/2014 Effective date: 5/15/2014 Therapeutic Classes reviewed: ADHD Ophthalmic antihistamines

More information

OH, MY ACHING HEAD! I HAVE NO DISCLOSURES OR CONFLICTS OF INTERESTS TO DECLARE MANAGING HEADACHE IN THE OUTPATIENT SETTING SECONDARY HEADACHES

OH, MY ACHING HEAD! I HAVE NO DISCLOSURES OR CONFLICTS OF INTERESTS TO DECLARE MANAGING HEADACHE IN THE OUTPATIENT SETTING SECONDARY HEADACHES 1 JUSTIN A. OSSMAN, MD CHATTANOOGA FAMILY MEDICINE UPDATE OH, MY ACHING HEAD! MANAGING HEADACHE IN THE OUTPATIENT SETTING 2 I HAVE NO DISCLOSURES OR CONFLICTS OF INTERESTS TO DECLARE OBJECTIVES International

More information

Optimizing triptan therapy in clinical practice

Optimizing triptan therapy in clinical practice Review Optimizing triptan therapy in clinical practice Carlo Lisotto* & Giorgio Zanchin Practice Points The prevalence of migraine is 12 16% of the general population and is two- to threetimes higher in

More information

Migraine Controversies in Women s Health. Professor Peter J. Goadsby 5 December Department of Neurology

Migraine Controversies in Women s Health. Professor Peter J. Goadsby 5 December Department of Neurology Migraine 2008 Controversies in Women s Health 5 December 2008 Professor Peter J. Goadsby Peter.Goadsby@headache.ucsf.edu Department of Neurology Headache International Headache Society Classification Primary

More information

Sumatriptan Injection (Imitrex / Alsuma / Sumavel / Zembrace)

Sumatriptan Injection (Imitrex / Alsuma / Sumavel / Zembrace) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.11 Subject: Sumatriptan Injection Page: 1 of 6 Last Review Date: March 17, 2017 Sumatriptan Injection

More information

Acute Migraine Treatment: What you and your family should know to help you make the best choices with your doctor

Acute Migraine Treatment: What you and your family should know to help you make the best choices with your doctor Acute Migraine Treatment: What you and your family should know to help you make the best choices with your doctor TAKE CONTROL OF YOUR MIGRAINES! ABOUT THIS PATIENT GUIDE: Migraine attacks are often debilitating

More information

M0BCore Safety Profile. Pharmaceutical form(s)/strength: ordispersible tablet SE/H/PSUR/0022/002 Date of FAR:

M0BCore Safety Profile. Pharmaceutical form(s)/strength: ordispersible tablet SE/H/PSUR/0022/002 Date of FAR: M0BCore Safety Profile Active substance: Zolmitriptan Pharmaceutical form(s)/strength: ordispersible tablet P-RMS: SE/H/PSUR/0022/002 Date of FAR: 15.03.2014 4.3 Contraindications Zolmitriptan is contraindicated

More information

Pharmacological treatment of attacks in juvenile migraine

Pharmacological treatment of attacks in juvenile migraine J Headache Pain (2004) 5:S62 S66 DOI 10.1007/s10194-004-0110-9 Beatrice Gallai Giovanni Mazzotta Paola Sarchielli Pharmacological treatment of attacks in juvenile migraine Received: Accepted in revised

More information

Disclosures. Objectives 6/2/2017

Disclosures. Objectives 6/2/2017 Classification: Migraine and Trigeminal Autonomic Cephalalgias Lauren Doyle Strauss, DO, FAHS Assistant Professor, Child Neurology Assistant Director, Child Neurology Residency @StraussHeadache No disclosures

More information

Management options for Migraine. Prof. Dr. Khwaja Nazimuddin Head Dept. of Internal Medicine BIRDEM

Management options for Migraine. Prof. Dr. Khwaja Nazimuddin Head Dept. of Internal Medicine BIRDEM Management options for Migraine Prof. Dr. Khwaja Nazimuddin Head Dept. of Internal Medicine BIRDEM Assessment The Migraine Disability Assessment Score MIDAS Complete loss of work Partial loss of work Off

More information

Triptan Quantity Limit

Triptan Quantity Limit *- Florida Healthy Kids Triptan Quantity Limit Override(s) Quantity Limit Approval Duration 1 year Oral Tablets Axert (almotriptan) tablets Relpax (eletriptan) tablets 6 tablets (6.25 mg) 12 tablets (12.5

More information

Migraine Management. Jane Melling Headache nurse Mater Misericordiae Hospital

Migraine Management. Jane Melling Headache nurse Mater Misericordiae Hospital Migraine Management Jane Melling Headache nurse Mater Misericordiae Hospital Migraine facts Among the most common disorders of the nervous system 3 rd most prevalent medical disorder on the planet (lancet

More information

ARTICLE. Migraine Therapeutics in Adolescents. A Systematic Analysis and Historic Perspectives of Triptan Trials in Adolescents

ARTICLE. Migraine Therapeutics in Adolescents. A Systematic Analysis and Historic Perspectives of Triptan Trials in Adolescents COMPARATIVE EFFECTIVENESS RESEARCH ARTICLE Migraine Therapeutics in Adolescents A Systematic Analysis and Historic Perspectives of Triptan Trials in Adolescents Haihao Sun, MD, PhD; Eric Bastings, MD;

More information

Within 24 hours of treatment with another 5-HT 1 agonist, or an ergotaminecontaining

Within 24 hours of treatment with another 5-HT 1 agonist, or an ergotaminecontaining HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use RELPAX safely and effectively. See full prescribing information for RELPAX. RELPAX (eletriptan hydrobromide)

More information

Medication For Migraine Chart: Table 1: Acute Treatment when the attack begins

Medication For Migraine Chart: Table 1: Acute Treatment when the attack begins Medication For Migraine Chart: Table 1: Acute Treatment when the attack begins Page a Analgesics (painkillers) Non-steroidal antiinflammatory drugs (NSAIDs) Prescription required Brand Name Formulation

More information

10/31/2017 PRIMARY CARE AND HEADACHE DISCLOSURES WHERE DO THOSE WITH HEADACHE SEEK MEDICAL CARE? Primary Care 67%

10/31/2017 PRIMARY CARE AND HEADACHE DISCLOSURES WHERE DO THOSE WITH HEADACHE SEEK MEDICAL CARE? Primary Care 67% PRIMARY CARE AND HEADACHE Sonja Potrebic MD PhD Regional Headache Specialist Kaiser LAMC 1 WHERE DO THOSE WITH HEADACHE SEEK MEDICAL CARE? Column1 Primary Care 67% Primary Care Headache Specialty Other

More information

Reviews/Evaluations. Medication-Overuse Headache

Reviews/Evaluations. Medication-Overuse Headache Reviews/Evaluations Medication-Overuse Headache Population-based studies suggest that the prevalence of chronic daily headache is 3-5%(1,2). Drug-induced headaches are the most common cause of chronic

More information

Migraine is an important clinical problem in

Migraine is an important clinical problem in REVIEW ARTICLE Symptomatic Treatment of Migraine in Children: A Systematic Review of Medication Trials Léonie Damen, PhD*; Jacques K. J. Bruijn, MD ; Arianne P. Verhagen, PhD*; Marjolein Y. Berger, MD

More information

A new questionnaire for assessment of adverse events associated with triptans: methods of assessment influence the results. Preliminary results

A new questionnaire for assessment of adverse events associated with triptans: methods of assessment influence the results. Preliminary results J Headache Pain (2004) 5:S112 S116 DOI 10.1007/s10194-004-0123-4 Michele Feleppa Fred D. Sheftell Luciana Ciannella Amedeo D Alessio Giancarlo Apice Nino N. Capobianco Donato M.T. Saracino Walter Di Iorio

More information

Drug Class Review on Triptans

Drug Class Review on Triptans Drug Class Review on UPDATED FINAL REPORT #1 December 2003 Mark Helfand, MD, MPH Kim Peterson, MS Oregon Evidence-based Practice Center Oregon Health & Science University Table of Contents Introduction

More information

Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose response study

Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose response study is effective and well tolerated in Japanese patients with migraine: a dose response study F Sakai 1, M Iwata 2, K Tashiro 3, Y Itoyama 4, S Tsuji 5, Y Fukuuchi 6, G Sobue 7, K Nakashima 8 & M Morimatsu

More information

Chronic Migraine in Primary Care. December 11 th, 2017 Werner J. Becker University of Calgary

Chronic Migraine in Primary Care. December 11 th, 2017 Werner J. Becker University of Calgary Chronic Migraine in Primary Care December 11 th, 2017 Werner J. Becker University of Calgary Disclosures Faculty: Werner J. Becker Relationships with commercial interests: Grants/Research Support: Clinical

More information

Jessica Ailani MD FAHS Director, Georgetown Headache Center Associate Professor Neurology Medstar Georgetown University Hospital

Jessica Ailani MD FAHS Director, Georgetown Headache Center Associate Professor Neurology Medstar Georgetown University Hospital Jessica Ailani MD FAHS Director, Georgetown Headache Center Associate Professor Neurology Medstar Georgetown University Hospital Honorarium from Current Pain and Headache Reports; Section Editor Unusual

More information

Drug Class Review on Triptans

Drug Class Review on Triptans Drug Class Review on Triptans Final Report Update 3 November 2005 Original Report Date: March 2003 Update 1 Report Date: December 2003 Update 2 Report Date: September 2004 A literature scan of this topic

More information

PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 5/18/17 SECTION: DRUGS LAST REVIEW DATE: 5/17/18 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 5/18/17 SECTION: DRUGS LAST REVIEW DATE: 5/17/18 LAST CRITERIA REVISION DATE: ARCHIVE DATE: ALLZITAL (butalbital and acetaminophen) 25 mg/325 mg oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific

More information

Neurologic Disorders: Headache in Children

Neurologic Disorders: Headache in Children 1 of 12 17/06/2014 7:57 PM Print Close Neurologic Disorders: Headache in Children Sharon Whiting, MBBS, FRCPC Date of revision: February 2014 Headaches occur commonly in children and adolescents. They

More information

Acute treatment of migraine in children and adolescents

Acute treatment of migraine in children and adolescents Acute treatment of migraine in children and adolescents Cristiano Termine, MD a,b Matteo Ferri, MD a,b Umberto Balottin, MD b,c a Child Neuropsychiatry Unit, Department of Clinical and Biological Sciences,

More information

Treatment of Headache in the ED

Treatment of Headache in the ED Treatment of Headache in the ED Benjamin W. Friedman, MD, MS, FAAEM Associate professor of Emergency Medicine Albert Einstein College of Medicine Montefiore Medical Center Disclosure Topics of Discussion

More information

Drug Class Review on the Triptans

Drug Class Review on the Triptans Drug Class Review on the Final Report March 7, 2003 Expires October 31, 2003 Mark Helfand, MD, MPH Kim Peterson, MS Produced by Oregon Health & Science University 3181 SW Sam Jackson Park Road Mailcode:

More information

Zolmitriptan nasal spray provides fast relief of migraine symptoms and is preferred by patients: a Swedish study of preference in clinical practice

Zolmitriptan nasal spray provides fast relief of migraine symptoms and is preferred by patients: a Swedish study of preference in clinical practice J Headache Pain (2004) 5:237 242 DOI 10.1007/s10194-004-0132-3 ORIGINAL Carl G.H. Dahlöf Mattias Linde Erika Kerekes Zolmitriptan nasal spray provides fast relief of migraine symptoms and is preferred

More information

Headaches in the Pediatric Emergency Dept

Headaches in the Pediatric Emergency Dept Headaches in Children February 23, 2011 Jinny Tavee, MD Associate Professor Neuromuscular Center Cleveland Clinic Foundation Cleveland, OH 1 Headaches in the Pediatric Emergency Dept Burton Gutierrez Kan

More information

Prevention and Treatment of Migraines CAITLIN BARNES, PHARM.D. CANDIDATE AMBULATORY CARE JOE CAMMILLERI, PHARM.D. NATOHYA MALLORY, PHARM.D.

Prevention and Treatment of Migraines CAITLIN BARNES, PHARM.D. CANDIDATE AMBULATORY CARE JOE CAMMILLERI, PHARM.D. NATOHYA MALLORY, PHARM.D. Prevention and Treatment of Migraines CAITLIN BARNES, PHARM.D. CANDIDATE AMBULATORY CARE JOE CAMMILLERI, PHARM.D. NATOHYA MALLORY, PHARM.D. Objectives Present patient case Review epidemiology/pathophysiology

More information

1. On how many days in the last 3 months did you miss work or school because of your headaches?

1. On how many days in the last 3 months did you miss work or school because of your headaches? The Migraine Disability Assessment Test The MIDAS (Migraine Disability Assessment) questionnaire was put together to help you measure the impact your headaches have on your life. The information on this

More information

ALSUMA (sumatriptan injection) 6 mg/0.5 ml for subcutaneous use Initial U.S. Approval: 1992

ALSUMA (sumatriptan injection) 6 mg/0.5 ml for subcutaneous use Initial U.S. Approval: 1992 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ALSUMA safely and effectively. See full prescribing information for ALSUMA. ALSUMA (sumatriptan injection)

More information

Approach to a Patient with Headache

Approach to a Patient with Headache Approach to a Patient with Headache J.D. Bartleson, MD Professor of Neurology Mayo Clinic College of Medicine 15 th Annual Internal Medicine Conference March 25, 2018 Boca Raton, FL 2014 MFMER slide-1

More information

Current Migraine Treatment Therapy. Daniel Kassicieh, DO, FAAN

Current Migraine Treatment Therapy. Daniel Kassicieh, DO, FAAN Current Migraine Treatment Therapy Daniel Kassicieh, DO, FAAN Migraine a Disease Process Migraines are a chronic disease process similar to many other chronic medical conditions Migraine has a low mortality

More information

Specific Care Question : Question Originator: Plain Language Summary from The Office of Evidence Based Practice: Conditional Recommendation

Specific Care Question : Question Originator: Plain Language Summary from The Office of Evidence Based Practice: Conditional Recommendation Ketorolac for Refractory Migraine in the ED Specific Care Question : In the pediatric patient diagnosed with refractory migraine is ketorolac an effective treatment? Question Originator: Migraine Therapy

More information

10/17/2017 CHRONIC MIGRAINES BOTOX: TO INJECT OR NOT INJECT? IN CHRONIC MIGRAINE PROPHYLAXIS OBJECTIVES PATIENT CASE EPIDEMIOLOGY EPIDEMIOLOGY

10/17/2017 CHRONIC MIGRAINES BOTOX: TO INJECT OR NOT INJECT? IN CHRONIC MIGRAINE PROPHYLAXIS OBJECTIVES PATIENT CASE EPIDEMIOLOGY EPIDEMIOLOGY BOTOX: TO INJECT OR NOT INJECT? IN CHRONIC MIGRAINE PROPHYLAXIS OBJECTIVES JENNIFER SHIN, PHARMD PGY2 AMBULATORY CARE PHARMACY RESIDENT COMMUNITYCARE HEALTH CENTERS PHARMACOTHERAPY ROUNDS OCTOBER 20, 2017

More information

Headaches in Children and Adolescents. Paul Shillito

Headaches in Children and Adolescents. Paul Shillito Headaches in Children and Adolescents Paul Shillito Topics For Discussion What s different about childhood migraine Chronic daily headache (CDH) Tumours and other things to worry about Management of childhood

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Allzital (butalbital-acetaminophen), butalbital-aspirin-caffeine, butalbitalaspirin-caffeine-codeine,

Allzital (butalbital-acetaminophen), butalbital-aspirin-caffeine, butalbitalaspirin-caffeine-codeine, Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Butalbital Analgesics Page: 1 of 6 Last Review Date: March 16, 2018 Butalbital Analgesics Description

More information

SIGN on the pharmacological management of migraine

SIGN on the pharmacological management of migraine GUIDELINES SIGN on the pharmacological management of migraine STEVE CHAPLIN In February 2018, the Scottish Intercollegiate Guidelines Network (SIGN) published a new guideline on the pharmacological management

More information